2-chloro-5-fluoro-N-methoxy-N-methylbenzamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-chloro-5-fluoro-N-methoxy-N-methylbenzamide
• 化学式: C₉H₉ClFNO₂
• 分子量: 217.627
• InChiKey: ZXFMIOLFKYQSJL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-chloro-5-fluoro-N-methoxy-N-methylbenzamide 在 一水合肼 作用下， 以 四氢呋喃 、 异丙醇 、 甲苯 为溶剂， 反应 22.0h， 生成 5-(2-chloro-5-fluorophenyl)-4-methyl-1H-pyrazole
  参考文献：
  名称：

  [EN] MONOACYLGLYCEROL LIPASE INHIBITORS AND USE THEREOF FOR THE TREATMENT OF ANXIETY
  [FR] INHIBITEURS DE MONOACYLGLYCÉROL LIPASE ET LEUR UTILISATION POUR LE TRAITEMENT DE L'ANXIÉTÉ

  摘要：

  Provided herein are methods of using reversible monoacylglycerol lipase (MAGL) inhibitors for the treatment of anxiety and related conditions, including Generalized anxiety disorder, panic disorder, social anxiety disorder, obsessive-compulsive disorder, post-traumatic stress disorder, separation anxiety disorder, anxious depression, and phobias, the methods comprising administering to the subject a therapeutically effective amount of a compound.

  公开号：

  WO2023130043A1
• 作为产物：
  描述：

  2-氯-5-氟苯甲酸 、 二甲羟胺盐酸盐 在 N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以87.3 %的产率得到2-chloro-5-fluoro-N-methoxy-N-methylbenzamide
  参考文献：
  名称：

  [EN] MONOACYLGLYCEROL LIPASE INHIBITORS AND USE THEREOF FOR THE TREATMENT OF ANXIETY
  [FR] INHIBITEURS DE MONOACYLGLYCÉROL LIPASE ET LEUR UTILISATION POUR LE TRAITEMENT DE L'ANXIÉTÉ

  摘要：

  Provided herein are methods of using reversible monoacylglycerol lipase (MAGL) inhibitors for the treatment of anxiety and related conditions, including Generalized anxiety disorder, panic disorder, social anxiety disorder, obsessive-compulsive disorder, post-traumatic stress disorder, separation anxiety disorder, anxious depression, and phobias, the methods comprising administering to the subject a therapeutically effective amount of a compound.

  公开号：

  WO2023130043A1

文献信息

• PI3K INHIBITORS AND METHODS OF MAKING AND USING THE SAME
  申请人：[en]RELAY THERAPEUTICS, INC.

  公开号：WO2024151930A1

  公开（公告）日：2024-07-18

  The disclosure is in part directed to solid forms of (S)-N-(8-(2-chloro-5-fluorophenyl)-3-(methylcarbamoyl)-6-oxo-5,6,7,8-tetrahydroimidazo[1,5-a]pyrazin-1-yl)benzo[d]isothiazole-3-carboxamide, its salts, its crystalline forms, and variants thereof.
• [EN] MONOACYLGLYCEROL LIPASE INHIBITORS AND USE THEREOF FOR THE TREATMENT OF ANXIETY<br/>[FR] INHIBITEURS DE MONOACYLGLYCÉROL LIPASE ET LEUR UTILISATION POUR LE TRAITEMENT DE L'ANXIÉTÉ
  申请人：[en]PSY THERAPEUTICS, INC.

  公开号：WO2023130043A1

  公开（公告）日：2023-07-06

  Provided herein are methods of using reversible monoacylglycerol lipase (MAGL) inhibitors for the treatment of anxiety and related conditions, including Generalized anxiety disorder, panic disorder, social anxiety disorder, obsessive-compulsive disorder, post-traumatic stress disorder, separation anxiety disorder, anxious depression, and phobias, the methods comprising administering to the subject a therapeutically effective amount of a compound.